Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
about
Integrated PK-PD and agent-based modeling in oncologyCurrent Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisA review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programLocalization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Remaining challenges in childhood cancer and newer targeted therapeutics.Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regressionInitial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activityDiscovery and preclinical development of vismodegib.Growth rate analysis and efficient experimental design for tumor xenograft studies.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsHuman microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.Retrospective growth kinetics and radiosensitivity analysis of various human xenograft models.Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).Translational value of mouse models in oncology drug development.Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.Current mathematical models for cancer drug discovery.Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.PKPD modeling of acquired resistance to anti-cancer drug treatment.Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.
P2860
Q27006577-4229A6CE-0354-4FA2-97A6-68045529D55AQ28077780-AF14077F-289F-4940-9E75-A310CEAAACFBQ33729213-435C912D-B6FA-4F56-A052-CAB56C2B18B1Q34561518-758C77DF-1F88-49E3-8CB7-F0DA6A4F9FF5Q34683835-4AC9D657-1AE2-42D4-972A-38A8D5C537F4Q35039240-3B70A543-00BA-4600-B1E2-9EF4D16E63D5Q35106844-33BEA1E3-87EF-4937-80D1-E5E4DA16C474Q35484712-7B5C0BD5-788D-47AB-85B6-C4A58B3B0E6FQ36040758-5984C184-152F-4ED6-A882-B07B48022B39Q36406956-0A259219-F858-4E03-96DA-A3B3C0F4CBB4Q37138952-EC1B8955-379A-4C28-A96D-D74D6993932FQ37668563-60A5AAA2-4DBA-44A6-B6DD-4A0CD9559366Q37709099-ED692DDD-8E28-4C31-8234-3B50D5636702Q37714557-C7F47674-2462-4A36-A59B-A445896C5CDBQ38214255-842E7B54-0A85-4B95-BDE0-FC2FE131467FQ38312548-5199B991-F28E-4CAE-9DF5-BB1928337BAFQ38351470-757D15C2-C89F-4FC0-A792-9E2AC36098A8Q38557331-146CCADF-4742-4824-8A40-2A7ED72FDBCEQ38703243-2A3CF63C-0E39-4F5D-94C3-C4505A635DA2Q38707936-F3747472-3AA3-46D8-A9E2-E175238CC250Q38722905-1C4EBC09-664B-4E86-A9CF-8B5FA6AAFD7CQ38764062-7C97D973-5891-4EA1-986D-8B7AEEACAA82Q38772200-5BE4AEF2-9437-402A-B896-367385EB6600Q38837564-C6331996-AB41-4ED6-BD19-1280A1B396E6Q38856969-02363E28-87BF-446B-8836-6F8A23A6132BQ38878056-6B7EE58F-F09F-41C5-9868-C2A485DF4F61Q38885290-A54A0C57-406B-40A2-BBE8-6EF14054E4FDQ38946966-22CFDEA5-0403-434D-9398-E43B28404104Q39112394-0EBB1DD1-42C3-4A6E-AC9A-BB91CDF1533BQ39359967-374925E0-E2B1-4EF0-B7DE-5DE0CA915D79Q41513317-00CB0B2D-DD64-468F-9351-EA11F8C4CBA5Q45746465-AF33109C-20CE-459B-8BDB-B468C088651BQ49787815-4FC68B49-3D5A-4A61-952F-2E31B142A2A4Q50057702-F9E0A9C7-30D7-4241-B461-7C59BD503C6FQ50242982-B9FA84D4-DA49-42A3-956D-CEF39D687FC0Q50985091-8B2D55E2-31D5-407F-AC94-C70EDD64BDC4Q51636999-27D45542-B121-4E74-9EB5-17372A38FF20Q53110628-30E06E1D-3DF7-429B-B0E1-39F39637E75AQ54478528-1EBCDF2C-9CF0-4BB8-9E87-D93E3C350299Q55329667-0C959CC1-A59B-426F-AE73-C2F24F1F2ECA
P2860
Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antitumor activity of targeted ...... elates with clinical response.
@en
Antitumor activity of targeted ...... elates with clinical response.
@nl
type
label
Antitumor activity of targeted ...... elates with clinical response.
@en
Antitumor activity of targeted ...... elates with clinical response.
@nl
prefLabel
Antitumor activity of targeted ...... elates with clinical response.
@en
Antitumor activity of targeted ...... elates with clinical response.
@nl
P2093
P1476
Antitumor activity of targeted ...... elates with clinical response.
@en
P2093
Bruno Alicke
Cornelis E C A Hop
Edna F Choo
Erin McNamara
Frank-Peter Theil
Harvey Wong
Jay Tibbitts
Lori S Friedman
P304
P356
10.1158/1078-0432.CCR-12-0738
P407
P577
2012-05-30T00:00:00Z